NF2 and neoplasm: Although the short-term primary outcome of target inhibition was negative, this demonstrates that sorafenib has the potential to modulate the immune microenvironment of NF2-SWN-related tumours as suggested in the present study which may alter the growth rate of these tumours over longer treatment windows.